337 related articles for article (PubMed ID: 17349846)
1. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Tokunaga Y; Sasaki H; Saito T
Surgery; 2007 Mar; 141(3):346-53. PubMed ID: 17349846
[TBL] [Abstract][Full Text] [Related]
2. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
Tokunaga Y; Takahashi K; Saito T
Hepatogastroenterology; 2005; 52(66):1715-21. PubMed ID: 16334763
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody.
Tokunaga Y; Nakagami M; Tokuka A; Ohsumi K
Anticancer Res; 2003; 23(2C):1763-8. PubMed ID: 12820455
[TBL] [Abstract][Full Text] [Related]
4. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
6. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
7. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.
Kai K; Kitajima Y; Hiraki M; Satoh S; Tanaka M; Nakafusa Y; Tokunaga O; Miyazaki K
Cancer Lett; 2007 Dec; 258(1):45-54. PubMed ID: 17892912
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between clinicopathological factors and enzymatic activity of orotate phosphoribosyl transferase (OPRT), dihydropyrimidine dehydrogenase (DPD) in esophageal cancer].
Takemura M; Yoshida K; Morimura K; Osugi H; Lee S; Kishida S
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1283-6. PubMed ID: 20647710
[TBL] [Abstract][Full Text] [Related]
9. The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
Oeda M; Yoshida K; Sanada Y; Wada Y; Suzuki T; Mizuiri H; Konishi K; Shigematsu H; Tanabe K; Fukushima M
Oncol Rep; 2006 Dec; 16(6):1165-72. PubMed ID: 17089033
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical and clinicopathological study of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase expression in oral cancer patients responding to UFT].
Kawasaki G; Yoshitomi I; Yanamoto S; Yamada S; Kawano T; Mizuno A
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1035-9. PubMed ID: 20567103
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between clinical pathologic factors and enzymatic activity of orotate Phosphoribosyl transferase (OPRT), Dihydropyrimidine dehydrogenase (DPD) and Thymidylate synthase (TS) in colorectal cancer].
Yamada T; Tanaka N; Yokoi K; Ishikawa N; Seya T; Kanazawa Y; Shirakawa T; Ohkawa K; Koizumi M; Ohaki Y; Yamashita K; Tajiri T
Gan To Kagaku Ryoho; 2006 Jun; 33(6):789-93. PubMed ID: 16770098
[TBL] [Abstract][Full Text] [Related]
12. Correlations of clinicopathological factors with protein expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in colorectal cancer.
Sumi T; Katsumata K; Tsuchida A; Ishizaki T; Shimazu M; Aoki T
Chemotherapy; 2010; 56(2):120-6. PubMed ID: 20407238
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between clinical pathophysiologic factors and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer].
Ochiai T; Sugitani M; Nishimura K; Noguchi H; Watanabe T; Sengoku H; Komiyama H; Okano M
Gan To Kagaku Ryoho; 2002 Mar; 29(3):413-20. PubMed ID: 11915731
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A
Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
[TBL] [Abstract][Full Text] [Related]
15. Expression of dihydropyrimidine dehydrogenase, orotate phosphoribosyl transferase and thymidylate synthase in patients with primary colorectal cancer, and associations with site of first metastasis.
Akagi Y; Kinugasa T; Mizobe T; Kawahara A; Kage M; Shirouzu K
Anticancer Res; 2012 Jun; 32(6):2277-82. PubMed ID: 22641663
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy.
Ochiai T; Nishimura K; Noguchi H; Kitajima M; Tsuruoka Y; Takahashi Y; Tsukada A; Watanabe E; Nagaoka I; Futagawa S
J Surg Oncol; 2006 Jul; 94(1):45-50. PubMed ID: 16788943
[TBL] [Abstract][Full Text] [Related]
17. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
[TBL] [Abstract][Full Text] [Related]
18. [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment].
Ishida H; Shirakawa K; Ohsawa T; Sobajima J; Hayashi Y; Nakada H; Yokoyama M; Hashimoto D
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1929-34. PubMed ID: 16282729
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
Oi K; Makino M; Ozaki M; Takemoto H; Yamane N; Nakamura S; Ikeguchi M; Kaibara N
Anticancer Res; 2004; 24(1):273-9. PubMed ID: 15015608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
